NEW YORK (GenomeWeb News) – Bruker and Nextval are collaborating on the high-throughput screening of drugs and their metabolites using both companies' platforms, Bruker announced today.

Bruker's ultrafleXtreme MALDI-TOF/TOF mass spectrometer and Nextval's MassInsight technology will be used in the partnership.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.